Nucleic acid aptamers have been proven to be a useful tool in many applications. Particularly, aptamers to epidermal growth factor receptor (EGFR) have been successfully used for the recognition of EGFR-expressing cells, the inhibition of EGFR-dependent pathways, and targeted drug delivery into EGFR-positive cells. Several aptamers are able to discriminate wild-type EGFR from its mutant form, EGFRvIII. Aptamers to EGFR have hairpin-like secondary structures with several possible folding variations. Here, an aptamer, previously selected to EGFRvIII, was chosen as a lead compound for extensive post-SELEX maturation. The aptamer was 1.5-fold truncated, the ends of the hairpin stem were appended with GC-pairs to increase thermal stability, and single pyrene modification was introduced into the aptamer to increase affinity to the target protein. Pyrene modification was selected from extensive computer docking studies of a library of thousands of chemicals to EGFR near the EGF-binding interface. The resulting aptamers bound extracellular domains of both variants of EGFR: EGFRwt and EGFRvIII with subnanomolar apparent dissociation constants. Compared with the initial aptamer, affinity to EGFRwt was increased up to 7.5-fold, whereas affinity to EGFRvIII was increased up to 4-fold.
Get full access to this article
View all access options for this article.
References
1.
NimjeeSM, WhiteRR, BeckerRC and SullengerBA. (2017). Aptamers as therapeutics. Ann Review Pharm Toxicol, 57:61–79.
2.
RozenblumGT, LopezVG, VitulloAD and RadrizzaniM. (2015). Aptamers: current challenges and future prospects. Exp Opin Drug Discov, 11:127–135.
3.
LiuX, WangP, ZhangC and MaZ. (2017). Epidermal growth factor receptor (EGFR): a rising star in the era of precision medicine of lung cancer. Oncotarget, 8:50209–50220.
4.
WangZ and FangS. (2014). EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer. Drug Des Develop Ther, 8:1595–1611.
5.
GanHK, CvrljevicAN and JohnsTG. (2013). The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered. FEBS J, 280:5350–5370.
6.
GrandalMV, ZandiR, PedersenMW, WillumsenBM, van DeursB and PoulsenHS. (2007). EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes. Carcinogenesis, 28:1408–1417.
7.
WangDL, SongYL, ZhuZ, LiXL, ZouY, YangHT, WangJJ, YaoPS, PanRJ, YangCJ and KangDZ. (2014). Selection of DNA aptamers against epidermal growth factor receptor with high affinity and specificity. Biochem Biophys Res Commun, 453:681–685.
8.
KimK, LeeSJ, RyuS and HanD. (2014). Efficient isolation and elution of cellular proteins using aptamer-mediated protein precipitation assay. Biochem Biophys Res Commun, 448:114–119.
9.
DamaseTR, MiuraTA, ParentCE and AllenPB. (2018). Application of the open qPCR instrument for the in vitro selection of DNA aptamers against epidermal growth factor receptor and drosophila C virus. ACS Comb Sci, 20:45–54.
10.
DamaseTR and AllenPB. (2019). Idiosyncrasies of thermofluorimetric aptamer binding assays. Biotechniques, 66:121–127.
11.
TanY, ShiYS, WuXD, LiangHY, GaoYB, LiSJ, ZhangXM, WangF and GaoTM. (2013). DNA aptamers that target human glioblastoma multiforme cells overexpressing epidermal growth factor receptor variant III in vitro. Acta Pharmacol Sinica, 34:1491–1498.
12.
WuX, LiangH, TanY, YuanC, LiS, LiX, LiG, ShiY and Zhang.X (2014). Cell-SELEX aptamer for highly specific radionuclide molecular imaging of glioblastoma in vivo. PLoS One, 9:e90752.
13.
LiuY, KuanCT, MiJ, ZhangX, ClaryBM, BignerDD and SullengerBA. (2009). Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis. Biol Chem, 390:137–144.
14.
LiN, NguyenHH, MB and Ellington.AD (2011). Inhibition of cell proliferation by an anti-EGFR aptamer. PLoS One, 6:e20299.
15.
EspositoCL, PassaroD, LongobardoI, CondorelliG, MarottaP, AffusoA, de FranciscisV and Cerchia.L (2011). A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death. PLoS One, 6:e24071.
16.
LiN, LarsonT, NguyenHH, SokolovKV and EllingtonAD. (2010). Directed evolution of gold nanoparticle delivery to cells. Chem Commun (Camb), 46:392–394.
17.
ChengS, JacobsonO, ZhuG, ChenZ, LiangSH, TianR, YangZ, NiuG, ZhuX and ChenX. (2019). PET imaging of EGFR expression using an 18F-labeled RNA aptamer. Eur J Nucl Med Mol Imaging, 46:948–956.
18.
ParkNJ, WangX, DiazA, Goos-RootDM, BockC, VaughtJD, SunW and Strom.CM (2013). Measurement of cetuximab and panitumumab-unbound serum EGFR extracellular domain using an assay based on slow off-rate modified aptamer (SOMAmer) reagents. PLoS One, 8:e71703.
19.
CamoraniS, CrescenziE, ColecchiaD, CarpentieriA, AmoresanoA, FedeleM, ChiarielloM and CerchiaL. (2015). Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells. Oncotarget, 6:37570–37587.
20.
ZhangX, PengL, LiangZ, KouZ, ChenY, ShiG, LiX, LiangY, WangF and ShiY. (2018). Effects of aptamer to U87-EGFRvIII Cells on the proliferation, radiosensitivity, and radiotherapy of glioblastoma cells. Mol Ther Nucleic Acids, 10:438–449.
21.
ShuD, LiH, ShuY, XiongG, CarsonWE, HaqueF, XuR and GuoP. (2015). Systemic delivery of anti-miRNA for suppression of triple negative breast cancer utilizing RNA nanotechnology. ACS Nano, 9:9731–9740.
22.
DongJ, CaoY, ShenH, MaQ, MaoS, LiS and SunJ. (2018). EGFR aptamer-conjugated liposome-polycation-DNA complex for targeted delivery of SATB1 small interfering RNA to choriocarcinoma cells. Biomed Pharmacother, 107:849–859.
23.
KimMW, JeongHY, KangSJ, ChoiMJ, YouYM, ImCS, LeeTS, SongIH, LeeCG, et al. (2017). Cancer-targeted nucleic acid delivery and quantum dot imaging using EGF receptor aptamer-conjugated lipid nanoparticles. Sci Rep, 7:9474.
24.
KimMW, JeongHY, KangSJ, JeongIH, ChoiMJ, YouYM, ImCS, SongIH, LeeTS, et al. (2019). Anti-EGF receptor aptamer-guided co-delivery of anti-cancer siRNAs and quantum dots for theranostics of triple-negative breast cancer. Theranostics, 9:837–852.
25.
KratschmerC and LevyM. (2018). Targeted delivery of auristatin-modified toxins to pancreatic cancer using aptamers. Mol Ther Nucleic Acids, 10:227–236.
26.
WanY, LiuY, AllenPB, AsgharW, MahmoodMAI, TanJ, DuhonH, KimYT, EllingtonAD and IqbalSM. (2012). Capture, isolation and release of cancer cells with aptamer-functionalized glass bead array. Lab Chip, 12:4693–4701.
27.
WangL, ZhengQ, ZhangQ, XuH, TongJ, ZhuC and WanY. (2012). Detection of single tumor cell resistance with aptamer biochip. Oncology Lett, 4:935–940.
28.
MelanconMP, ZhouM, ZhangR, XiongC, AllenP, WenX, HuangQ, WallaceM, MyersJN, et al. (2014). Selective uptake and imaging of aptamer- and antibody-conjugated hollow nanospheres targeted to epidermal growth factor receptors overexpressed in head and neck cancer. ACS Nano, 85:4530–4538.
29.
TangJ, HuangN, ZhangX, ZhouT, TanY, PiJ, PiL, ChengS, ZhengH and ChengY. (2017). Aptamer-conjugated PEGylated quantum dots targeting epidermal growth factor receptor variant III for fluorescence imaging of glioma. Int J Nanomed, 12:3899–3911.
30.
ZavyalovaEG, LegatovaVA, AlievaRS, ZalevskyAO, TashlitskyVN, ArutyunyanAM, and Kopylov.AM (2019). Putative mechanisms underlying high inhibitory activities of bimodular DNA aptamers to thrombin. Biomolecules, 9:41.
TangeO. (2011). GNU Parallel—the command-line power tool. USENIX Mag, 36:42–47.
34.
TrottO and OlsonAJ. (2010). AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comput Chem, 31:455–461.
35.
SickmierEA, KurzejaRJM, MichelsenK, VazirM, YangE and Tasker.AS (2016). The panitumumab EGFR complex reveals a binding mechanism that overcomes cetuximab induced resistance. PLoS One, 11:e0163366.
36.
TataurovAV, YouY and OwczarzyR. (2008). Predicting ultraviolet spectrum of single stranded and double stranded deoxyribonucleic acids. Biophys Chem, 133:66–70.
37.
MergnyJ-L and LacroixL. (2003). Analysis of thermal melting curves. Oligonucleotides, 13:515–537.
38.
SkoblovAY, VichuzhaninMV, FarzanVM, VeselovaOA, KonovalovaTA, PodkolzinAT, ShipulinGA and ZatsepinTS. (2015). Solid- and solution-phase synthesis and application of R6G dual-labeled oligonucleotide probes. Bioorg Med Chem, 23:6749–6756.
ButinaD. (1999). Unsupervised data base clustering based on daylight's fingerprint and Tanimoto similarity: a fast and automated way to cluster small and large data sets. J Chem Inf Comput Sci 39:. 747–750.
OkamotoA, KanataniK and SaitoI. (2004). Pyrene-labeled base-discriminating fluorescent DNA probes for homogeneous SNP typing. J Am Chem Soc, 126:4820–4827.
43.
GruberAR, LorenzR, BernhartSH, NeuböckR and HofackerIL. (2008). The Vienna RNA websuite. Nucleic Acids Res, 36:W70–W74.
44.
KrallJA, BeyerEM and MacBeath.G (2011). High- and low-affinity epidermal growth factor receptor-ligand interactions activate distinct signaling pathways. PLoS One, 6:e15945.
45.
JonesJT, AkitaRW and SliwkowskiMX. (1999). Binding specificities and affinities of EGF domains for ErbB receptors. FEBS Lett, 447:227–231.
46.
WangT, ChenC, LarcherLM, BarreroRA and VeeduRN. (2019). Three decades of nucleic acid aptamer technologies: lessons learned, progress and opportunities on aptamer development. Biotechnol Adv, 37:28–50.
47.
ZhangF, WangS, YinL, YangY, GuanY, WangW, XuH and TaoN. (2015). Quantification of epidermal growth factor receptor expression level and binding kinetics on cell surfaces by surface plasmon resonance imaging. Anal Chem, 87:9960–9965.
NovoseltsevaA, ZavyalovaE, GolovinA and KopylovA. (2018). An insight into aptamer–protein complexes. Aptamers, 2:1–19.
50.
RohloffJC, GelinasAD, JarvisTC, OchsnerUA, SchneiderDJ, GoldL and Janjic.N (2014). Nucleic acid ligands with protein-like side chains: modified aptamers and their use as diagnostic and therapeutic agents. Mol Ther Nucleic Acids, 3:e201.
51.
AntipovaOM, ZavyalovaEG, GolovinAV, PavlovaGV, KopylovAM and ReshetnikovRV. (2018). Advances in the application of modified nucleotides in SELEX technology. Biochemistry (Mosc), 83:1161–1172.
52.
MayawalaK, VlachosDG and EdwardsJS. (2005). Heterogeneities in EGF receptor density at the cell surface can lead to concave up scatchard plot of EGF binding. FEBS Lett, 579:3043–3047.
53.
YamanaK, OhtaniY, NakanoH and SaitoI. (2003). Bis-pyrene labeled DNA aptamer as an intelligent fluorescent biosensor. Bioorg Med Chem Lett, 13:3429–3431.
MichaelE. Østergaard and Patrick J. Hrdlicka. (2011). Pyrene-functionalized oligonucleotides and locked nucleic acids (LNAs): tools for fundamental research, diagnostics, and materials science. Chem Soc Rev, 40:5771–5788.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
